FDA Exclusive: a Spotlight on Regulation in Antibacterial Drug Development

22:00 EST 1 Dec 2016 |

London, United Kingdom, December 02, 2016 --( SMi Group are thrilled to have industry expert Sumathi Nambair, provide regulatory and compliance updates on FDA legislation in antibacterial drug development at the 19th annual 2017 Superbugs & Superdrugs show, returning to Central London on 20th and 21st March.

The long running event will once again gather a global audience of scientific leaders, government bodies and anti-infective specialists, providing a focal point to discuss the global action plan on antimicrobial resistance.

In her current role at the FDA, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs. Her keynote presentation will explore FDA development programmes and activities to facilitate antibiotic drug discovery.

SMi Group are also delighted to welcome the expertise of Xavier Duportet, CEO from Eligo Bioscience who has recently confirmed to speak. Following a €2M deal from leading microbiome investor, Seventure, the talk will offer progressive insight into sequence-specific antimicrobials for targeted eradication of carriage.

The notable speaker line-up on at Superbugs & Superdrugs 2017 will also include:
Richard Bax, Senior Partner, TranScrip
Lloyd Czaplewski, Director, Chemical Biology Ventures
Chris Houchens, Branch Chief, BARDA
James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline
Aileen Rubio, Head of Biology, Spero Therapeutics
David Williams, Chief Executive Officer, Discuva
Martin Everett, Chief Scientific Officer, ANTABIO SAS
Jean de Gunzburg, Scientific Director, Da Volterra
William J Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy

For those looking to attend there is currently a £400 saving available online ending on 30th November 2017. More information is available online at

Superbugs & Superdrugs 2017
20TH & 21ST March
Copthorne Tara Hotel, London, UK

Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email:
For delegate enquires contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email:
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email:

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Contact Information:
SMi Group
Teri Arri
+44 (0) 20 7827 6000
Contact via Email

Read the full story here:

Press Release Distributed by

Original Article: FDA Exclusive: a Spotlight on Regulation in Antibacterial Drug Development


More From BioPortfolio on "FDA Exclusive: a Spotlight on Regulation in Antibacterial Drug Development"

Quick Search

Relevant Topic

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...